Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc.

Overview
Date Founded

1935

Headquarters

616 N. North Court, Suite 120, Palatine, IL, 60067, USA

Type of Company

Public

Employees (Worldwide)

13

Industries

Pharmaceuticals
IT Consulting & Services
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

Acura Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of abuse deterrent, orally administered pharmaceutical products. Its technology platforms include AVERSION, IMPEDE, and LIMITX. The company was founded on April 10, 1935 and is headquartered in Palatine, IL.

Contact Data
Trying to get in touch with decision makers at Acura Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Senior Vice President & Chief Financial Officer

Senior Director Quality & Analytical Chemistry

Vice President, Treasurer & Corporate Controller

Director-Logistics & Special Projects

Director of EHS & Engineering

Vice President, Pharmaceutical Sciences

Vice President, Corporate Development

Early Stage Business Consultant

Board of Directors

Managing Director at Essex Woodlands Management, Inc.

Early Stage Business Consultant at Acura Pharmaceuticals, Inc.

Founding Partner Emeritus at Galen Management Services Ltd.

President & Chief Executive Officer at Central Biomedia, Inc.

Paths to Acura Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Acura Pharmaceuticals, Inc.
Clients

Zyla Life Sciences is a commercial-stage company, which focuses on developing, manufacturing and commercializing innovative treatments for pain. It is focused on bringing non-narcotic products and abuse-discouraging formulations of opioids to patients and healthcare providers. The company plans to continue to grow revenue of its seven commercial products, which includes Sprix nasal spray, Vivlodex, Zorvolex, Tivorbex, Indocin suppositories, Indocin oral suspension and oxaydo tablets, and explore business development opportunities. Zyla Life Sciences was founded in August 2013 and is headquartered in Wayne, PA.

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses in the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Coralville, IA.

Key Stats and Financials As of 2018
Market Capitalization
$9.16M
Total Enterprise Value
$6.56M
Earnings Per Share
$-0.18
Revenue
$410K
TEVNet Income
-1.71x
Debt TEV
0.64x
Enterprise Value Sales
16.01x
Total Debt
$4.22M
Total Equity
$-3.62M
Net Profit
$-3.84M
EBITDAMargin
-886.59%
EBITDA
$-3.64M
Investors
Details Hidden

Managing Partner at Vivo Capital LLC

Details Hidden
Competitors
Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Sun Pharmaceutical Industries Ltd. Pharmaceuticals - Mumbai, MA

Sun Pharmaceutical We are an international speciality pharma company, with a large presence in the US and India, and a footprint across 41 other markets. In the US, which is our largest market, we have built a strong pipeline of generics, directly and through our subsidiaries Caraco and Sun Pharmaceutical Inc. Taro adds strong dermatology range to this portfolio. In India and rest of the world markets, our brands are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, diabetology, ophthalmology, orthopedics etc. We are market leaders in speciality therapy areas in India. We retain the drive for growth that marked our early days, when we had. begun in 1983 with just 5 products. Since then, we have crossed several milestones to emerge as a leading pharma company in India where we are the 5th largest by prescription sales, a rank that we have retained over a decade. (IMS ORG Stockist Audit, March. 2012) Since the mid- nineties, we have used a combination of growth and acquisition to drive growth. important acquisitions have included those of the US, detroit-based Caraco Parma Labs and a plant at Halol which now holds UKMHRA and USFDA approvals. The 2010 acquisition of Taro Pharmaceuticals doubles our US business and brings us strengths in dermatology and pediatrics

Collegium Pharmaceutical, Inc. Pharmaceuticals - Canton , MA

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in October 2003 and is headquartered in Stoughton, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Acura Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Acura Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Acura Pharmaceuticals, Inc..